GENETIC ANALYSIS NK -60 (8V8) — Capital Reinvestment Ratio
Latest as of December 2025:
0.17x
GENETIC ANALYSIS NK -60 (8V8) has a Capital Reinvestment Ratio of 0.17x as of December 2025, meaning it reinvests 0% of its operating cash flow (€8.04 Million) in capital expenditures (€1.36 Million). See GENETIC ANALYSIS NK -60 (8V8) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.17x
Capex / Operating Cash Flow
Operating Cash Flow
€8.04 Million
EUR
Capital Expenditures
€1.36 Million
EUR
Data as of
Dec 2025
Most recent filing
GENETIC ANALYSIS NK -60 Capital Reinvestment Ratio (2025–2025)
This chart tracks GENETIC ANALYSIS NK -60's Capital Reinvestment Ratio across 1 annual periods.
Annual Capital Reinvestment Ratio for GENETIC ANALYSIS NK -60 (2025–2025)
Year-by-year Capital Reinvestment Ratio for GENETIC ANALYSIS NK -60 from 2025 to 2025. For live market cap and broader valuation context, see GENETIC ANALYSIS NK -60 stock valuation.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 2.31x | €2.40 Million | €5.54 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow